Sunesis Pharmaceuticals - Inspired to Make a Difference in Cancer Patients Lives.

Overview

Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, including its first-in-class PDK1 inhibitor SNS-510.

More »
|  (Common Stock)
Stock chart for: SNSS.O.  Currently trading at $2.56 with a 52 week high of $6.30 and a 52 week low of $2.51.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

More »